Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jul;50(9):2572-2575.
doi: 10.1007/s00259-023-06287-0.

European guidelines update on PSMA PET/CT for prostate cancer staging-snap back to reality

Fabrizia Gelardi  1   2 , Alberto Briganti  1   3 , Cristiano Pini  4   5 , Gaia Ninatti  6   7 , Giorgio Gandaglia  1   3 , Francesco Montorsi  1   3 , Arturo Chiti  1   6
Affiliations
Editorial

European guidelines update on PSMA PET/CT for prostate cancer staging-snap back to reality

Fabrizia Gelardi et al. Eur J Nucl Med Mol Imaging. 2023 Jul.
No abstract available

PubMed Disclaimer

References

    1. O’Keefe DS, Bacich DJ, Huang SS, Heston WDW. A perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies. Journal of Nuclear Medicine [Internet]. Society of Nuclear Medicine and Molecular Imaging; 2018;59:1007. Retrieved Apr 11, 2023, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910646/
    1. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 Update: treatment of Relapsing and Metastatic Prostate Cancer[Formula presented]. Eur Urol. 2021;79:263–82.
    1. Lisney AR, Leitsmann C, Strauß A, Meller B, Bucerius JA, Sahlmann CO. The role of PSMA PET/CT in the primary diagnosis and follow-up of prostate cancer—a practical clinical review. Cancers. 2022;14:3638 [Internet]. Multidisciplinary Digital Publishing Institute; 2022 [cited 2023 Apr 11];14:3638. Available from: https://www.mdpi.com/2072-6694/14/15/3638/htm
    1. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med [Internet]. N Engl J Med; 2021 [cited 2023 May 10];385:1091–103. Available from: https://pubmed.ncbi.nlm.nih.gov/34161051/
    1. Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet [Internet]. Lancet; 2021 [cited 2023 May 10];397:797–804. Available from: https://pubmed.ncbi.nlm.nih.gov/33581798/

Publication types

LinkOut - more resources